Cargando…

The restricted mean survival time as a replacement for the hazard ratio and the number needed to treat in long‐term studies

AIMS: We applied the restricted mean survival time (RMST) to analyse the survival data reported in the PARADIGM‐HT trial in which sacubitril + valsartan was studied in comparison with enalapril in patients with heart failure. The estimates of this parameter were compared with the published values of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Messori, Andrea, Bartoli, Laura, Trippoli, Sabrina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Short Communications
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8120383/ https://www.ncbi.nlm.nih.gov/pubmed/33733623 http://dx.doi.org/10.1002/ehf2.13306

Ejemplares similares

Value-based procurement of prostheses for total knee replacement
por: Messori, Andrea, et al.
Publicado: (2018)

Handling the procurement of prostheses for total hip replacement: description of an original value based approach and application to a real-life dataset reported in the UK
por: Messori, Andrea, et al.
Publicado: (2017)

Simplified figure to present direct and indirect comparisons: Revisiting the graph 10 years later
por: Fadda, Valeria, et al.
Publicado: (2021)

Early and intermediate survival after transcatheter aortic valve implantation: systematic review and meta-analysis of 14 studies
por: Messori, Andrea, et al.
Publicado: (2013)

Infections in Patients Receiving Subcutaneous Biological Treatments for Moderate to Severe Psoriasis
por: Messori, Andrea, et al.
Publicado: (2015)

Estimation of Value-Based Price for Five High-Technology Medical Devices Approved by a Regional Health Technology Assessment Committee in Italy
por: Messori, Andrea, et al.
Publicado: (2022)

Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome
por: Royston, Patrick, et al.
Publicado: (2013)

Differences in Effectiveness among Devices for Endovascular Thrombectomy in Patients with Acute Ischemic Stroke
por: Chiumente, Marco, et al.
Publicado: (2016)

Correlation of Milestone Restricted Mean Survival Time Ratio With Overall Survival Hazard Ratio in Randomized Clinical Trials of Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis
por: Wang, Zi-Xian, et al.
Publicado: (2019)

Antithrombin III in patients admitted to intensive care units: a multicenter observational study
por: Messori, Andrea, et al.
Publicado: (2002)

The limitations of observational studies on the treatment of severe sepsis – authors' response
por: Messori, Andrea, et al.
Publicado: (2002)

Estimation of Value-Based Price for 48 High-Technology Medical Devices
por: Hyeraci, Giulia, et al.
Publicado: (2023)

Medical Therapy, Radiofrequency Ablation, or Cryoballoon Ablation as First-Line Treatment for Paroxysmal Atrial Fibrillation: Interpreting Efficacy Through the Shiny Method
por: Trippoli, Sabrina, et al.
Publicado: (2022)

Managing Tenders in the Procurement of Advanced Medical Devices: An Original Model Based on the Net Monetary Benefit Combined With Three Clinical Endpoints
por: Messori, Andrea, et al.
Publicado: (2023)

Testing the Therapeutic Equivalence of Alogliptin, Linagliptin, Saxagliptin, Sitagliptin or Vildagliptin as Monotherapy or in Combination with Metformin in Patients with Type 2 Diabetes
por: Messori, Andrea, et al.
Publicado: (2014)

New Oral Anticoagulants in Acute Coronary Syndrome: Is There Any Advantage Over Existing Treatments?
por: Messori, Andrea, et al.
Publicado: (2014)

Subcutaneous Biological Treatments for Moderate to Severe Psoriasis: Interpreting Safety Data by Network Meta-Analysis
por: Messori, Andrea, et al.
Publicado: (2015)

Biological drugs for inducing remission in patients with Crohn's disease: determining statistical equivalence according to evidence-based methods
por: Messori, Andrea, et al.
Publicado: (2015)

Survival in patients with intermediate or high grade non-Hodgkin's lymphoma: meta-analysis of randomized studies comparing third generation regimens with CHOP
por: Messori, A, et al.
Publicado: (2001)

Axicabtagene ciloleucel in non-Hodgkin lymphoma: the restricted mean survival time as a tool for estimating progression-free life expectancy better than the median
por: Messori, Andrea, et al.
Publicado: (2020)

A Comparison of Statistical Analysis Between "Real" Patients Reported in Kaplan-Meier Curves and "Reconstructed" Patients Estimated Through the IPDfromKM Method: Analysis of Eight Trials Evaluating Catheter Ablation of Ventricular Tachycardia
por: Messori, Andrea, et al.
Publicado: (2023)

Bayesian test for hazard ratio in survival analysis
por: Kim, Gwangsu, et al.
Publicado: (2016)

Relationship Between Price and Diagnosis-Related Group Tariff for Medical Devices Assessed by a Regional Health Technology Assessment Committee
por: Trippoli, Sabrina, et al.
Publicado: (2022)

Hazard ratio
por: Trkulja, Vladimir, et al.
Publicado: (2019)

Individual patient data network meta-analysis using either restricted mean survival time difference or hazard ratios: is there a difference? A case study on locoregionally advanced nasopharyngeal carcinomas
por: Petit, C., et al.
Publicado: (2019)

An alternative approach for estimating the number needed to treat for survival endpoints
por: Yang, Zhao, et al.
Publicado: (2019)

Restricted mean survival time of older adults with severe aortic stenosis referred for transcatheter aortic valve replacement
por: Rodighiero, Julia, et al.
Publicado: (2020)

Reduction in number to treat versus number needed to treat
por: Zhang, Chenyang, et al.
Publicado: (2021)

Why so many sperm cells? Not only a possible means of mitigating the hazards inherent to human reproduction but also an indicator of an exaptation
por: Barlow, Peter W.
Publicado: (2016)

SARS-COV-2 pandemic: establishing three risk levels for 19 Italian regions and two autonomous provinces
por: Messori, Andrea, et al.
Publicado: (2022)

Acetaminophen: A hazard to immunotherapy
por: Najeebullah, et al.
Publicado: (2022)

Lymph Node Ratio after Neoadjuvant Chemotherapy for Stage II/III Breast Cancer: Prognostic Value Measured with Gini’s Mean Difference of Restricted Mean Survival Times
por: Keam, Bhumsuk, et al.
Publicado: (2021)

Numbers needed to treat to prevent tuberculosis
por: Matteelli, Alberto, et al.
Publicado: (2015)

The number needed to treat adjusted for explanatory variables in regression and survival analysis: Theory and application
por: Vancak, Valentin, et al.
Publicado: (2022)

Limitations of the incidence density ratio as approximation of the hazard ratio
por: Bender, Ralf, et al.
Publicado: (2019)

Health Hazards Linked to Festivals: An Overview
por: Aboud, Khalid Al
Publicado: (2013)

What’s the Risk: Differentiating Risk Ratios, Odds Ratios, and Hazard Ratios?
por: George, Andrew, et al.
Publicado: (2020)

Restricted Mean Survival Time for Survival Analysis: A Quick Guide for Clinical Researchers
por: Han, Kyunghwa, et al.
Publicado: (2022)

Prevalent cases in observational studies of cancer survival: do they bias hazard ratio estimates?
por: Azzato, E M, et al.
Publicado: (2009)

Log-Rank Test vs MaxCombo and Difference in Restricted Mean Survival Time Tests for Comparing Survival Under Nonproportional Hazards in Immuno-oncology Trials: A Systematic Review and Meta-analysis
por: Mukhopadhyay, Pralay, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_tb6q5psn3b9atueq5ffs7svt7t